Mixtard 30 Flexpen (Insulin Human)

Insulin human is a recombinant form of human insulin that binds to insulin receptors on muscle, fat and liver cells. This binding activates intracellular pathways that move glucose‑transport proteins to the cell surface, allowing glucose to enter cells for energy use or storage, while simultaneously suppressing the liver’s production of new glucose.

The dose of Mixtard 30 Flexpen is individualized by the prescribing healthcare professional. It is based on factors such as the patient’s current blood‑glucose readings, dietary habits, physical activity, renal function and overall response to therapy. Patients should follow the prescriber’s instructions and adjust only under medical guidance.

Data on the use of insulin human in pregnancy and lactation are limited. Insulin is generally considered the preferred glucose‑lowering therapy when needed during pregnancy, but the decision should be made by the treating physician after weighing potential benefits against any unknown risks. Breastfeeding mothers should consult their doctor before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling where required—and assistance with import documentation.

Mixtard 30 Flexpen is a premixed insulin that combines rapid‑acting and intermediate‑acting components in a fixed 30%/70% ratio. Compared with basal‑only insulins, it offers both mealtime and background coverage in a single injection, reducing injection frequency. Unlike separate rapid‑acting and basal pens, dose flexibility between the two components is limited, which may be advantageous for patients preferring simplicity.

The Flexpen should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep it in the original packaging, protect it from light, and avoid freezing. Once in use, the pen may be kept at controlled room temperature (up to 30 °C) for up to 28 days, but it must never be shaken vigorously.

Mixtard 30 Flexpen is administered subcutaneously using the built‑in pen mechanism. The injection sites include the abdomen, thigh, upper arm or buttock, rotating sites with each dose. Patients should clean the skin with an alcohol swab, attach a new needle, set the prescribed dose, and inject at a 90‑degree angle, following the pen’s instructions.

The most serious risks include severe hypoglycaemia, which can cause confusion, loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Rare but serious events such as hypokalemia, acute pancreatitis or severe injection‑site infections have also been reported. Prompt medical attention is required if any of these occur.

Mixtard 30 Flexpen should not be used by individuals with a known hypersensitivity to insulin human or any of the pen’s excipients. It is also contraindicated in patients with severe hypoglycaemia unawareness who cannot recognize low‑glucose symptoms, and in those with certain endocrine disorders where insulin therapy is inappropriate without specialist supervision.